GBV006 – a potent anti-infective being developed for a broad spectrum of viral indications

Globavir's lead infectious disease therapeutic technology, GBV006, is a combination of two previously approved drugs subject to the expedited 505(b)(2) regulatory pathway. GBV006 has shown very promising in vivo activity against Ebola and Dengue virus, and is currently in Phase II trials for Ebola with Phase Ib/IIa trials for Dengue expected to begin in H2 2016. Globavir is further investigating promising preclinical data targeting additional indications with unmet needs, such as Respiratory Syncytial Virus.